French Parliament Public Hearing on Biosimilar Medicines, Paris, 29 January 2015 – Intervention from EMA Spokesperson Camille Vleminckx

French_Parliament_Public_Hearing_on_Biosimilar_Medicines_1

Labelling & Naming – EBG Perspective, DIA Berlin 2014

Sans-titre-4

WHO BQ Proposal – EGA’s perspective, 59th INN Consultation, WHO, Geneva, 14 October 2014

Sans-titre-4

EMA mAb Workshop – Guideline on Similar Biological Medicinal Products

EMA mAb Workshop – Quality Target Product Profile in the Development of a Biosimilar

EMA mAb Workshop – Stepwise Approach to Non-Clinical Program

International Generic Pharmaceutical Alliance (IGPA) Letter Regarding TGA Guidance Titled “Evaluation of Biosimilars”, 2013

Sans-titre-4

Safe Prescription,Safe Dispensing, Identification and Track&Trace of All Biologicals in the Context of the Re-opened Biosimilars INN Debate – 11th EGA Symposium on Biosimilar Medicines, Suzette Kox, London 2013

Biosimilar Monoclonal Antibodies – 11th EGA International Symposium on Biosimilar Medicines, Gudbjorg Edda Eggertsdottir, London, 25 April 2013

Production and Control of Biosimilars versus Innovators, Biosimilars Present and Future – Da Silva, Infarmed, Lisbon, 3 April 2013 (PPT)

Sans-titre-4

Medicines For Europe